MedPath

Tagged News

City of Hope Receives $23.7 Million ARPA-H Grant to Map Immunotherapy Resistance in Lung Cancer

Precision Medicine
  • City of Hope has been awarded up to $23.7 million by ARPA-H to create a biomap of tumor changes causing immunotherapy resistance in advanced non-small cell lung cancer.
  • The six-year clinical trial will enroll 535 patients and use real-time monitoring techniques including liquid biopsies and single-cell sequencing to track tumor evolution.
  • Researchers aim to improve progression-free survival by 50% in at least one patient group by adapting treatments as resistance develops.
  • The project addresses the limited reliability of current biomarkers, with existing immunotherapy response rates below 40% in NSCLC patients.

Ashvattha Therapeutics Unveils Novel Nanomedicine Radiotracers for Neuroinflammation and Cancer Imaging at SNMMI 2025

Precision MedicineOncology
  • Ashvattha Therapeutics will present data on two breakthrough nanomedicine radiotracers at the SNMMI Annual Meeting, demonstrating selective targeting capabilities in neuroinflammation and cancer.
  • The company's flurimedrimer radiotracer selectively targets activated microglia in the human brain, supporting development of precision imaging tools for neurological conditions.
  • A second radiotracer designed to target tumor-associated macrophages shows potential for advancing precision imaging in oncology applications.
  • The data demonstrates the versatility of Ashvattha's hydroxyl dendrimer platform to achieve selective uptake in different inflammatory environments across therapeutic areas.

Agenus Partners with Noetik to Develop AI-Powered Biomarkers for Precision Immunotherapy

AIPrecision MedicineMonoclonal Antibody
  • Agenus and Noetik announced a research collaboration to develop predictive biomarkers for the BOT/BAL immunotherapy combination using AI-powered virtual cell models.
  • The partnership leverages Noetik's OCTO foundation model, trained on data from nearly 200 million tumor and immune cells across thousands of patients with various cancer types.
  • The collaboration aims to identify which patients are most likely to respond to botensilimab and balstilimab treatment, potentially improving clinical trial outcomes and patient care.
  • Botensilimab has been evaluated in over 1,200 patients across nine tumor types and has shown responses even in immunotherapy-resistant "cold" tumors.

PHOENIX Study Launches World's Largest Pharmacogenomics Trial to Personalize Drug Prescribing in Scotland

Precision Medicine
  • The PHOENIX Study, one of the largest pharmacogenomics trials globally, will recruit up to 4,000 patients over two years to investigate how genetic profiles affect responses to 60 commonly prescribed NHS medications.
  • Around 15% of patients are expected to carry genetic variants that may reduce medication effectiveness or increase side effects, which currently go unnoticed without genetic testing.
  • Led by Professor Sandosh Padmanabhan at the University of Glasgow, the trial aims to provide real-world evidence for implementing precision medicine across Scotland's healthcare system.
  • Participants undergo simple genetic testing with results returned within days to help doctors determine optimal drug selection and dosing based on individual genetic makeup.

UCSF Researchers Develop CAR-T Therapy for Aggressive Bladder Cancer Variant Using Novel Biomarkers

CAR-TPrecision Medicine
  • UCSF scientists identified CA125 and TM4SF1 as novel biomarkers in histologic variant bladder cancer, which affects up to 25% of bladder cancer patients but is typically excluded from clinical trials.
  • Researchers developed CAR-T cell therapy targeting TM4SF1 protein that successfully eliminated bladder tumors in preclinical mouse models.
  • The breakthrough uses single-cell sequencing technology to characterize previously untreatable bladder cancer subtypes that resist conventional therapy and frequently recur after surgery.
  • This discovery could transform treatment options for patients with histologic variant bladder cancer who currently have limited therapeutic alternatives beyond radical surgery.

Incyte's INCA033989 Shows 86% Response Rate in CALR-Mutant Blood Cancer Trial

Monoclonal AntibodyPrecision Medicine
  • Incyte's experimental monoclonal antibody INCA033989 demonstrated an 86% complete or partial hematologic response rate in patients with CALR-mutant myeloproliferative neoplasms receiving doses of 400 mg or higher.
  • The company announced a precision medicine collaboration with Qiagen to develop next-generation sequencing diagnostics for detecting CALR mutations, the second most common driver of MPNs.
  • Clinical data from dose-escalation studies showed 89% of evaluable patients had reduced mutant CALR variant allele frequency, with 21% achieving partial molecular response within three treatment cycles.
  • Stifel upgraded Incyte to 'Buy' rating with a $107 price target following the encouraging clinical results presented at the European Hematology Association congress.

Pierre Fabre Acquires Global Rights to Next-Generation EGFR Inhibitors for NSCLC Treatment

Targeted TherapyPrecision MedicineOncology
  • Pierre Fabre Laboratories acquired worldwide rights to PFL-721 and PFL-241 from Antares Therapeutics, expanding their oncology pipeline with mutant-specific EGFR inhibitors targeting unmet needs in non-small cell lung cancer.
  • PFL-721 is a dual EGFR exon 20 and HER2 exon 20 inhibitor transitioning to dose optimization in first-in-human trials, while PFL-241 is a brain-penetrant fourth-generation EGFR inhibitor addressing C797S resistance mutations.
  • EGFR mutations drive approximately 14-38% of NSCLC tumors globally, representing a significant patient population with substantial therapeutic needs.
  • The acquisition consolidates Pierre Fabre's complete ownership of their R&D portfolio including exarafenib and PFL-002, positioning the company to advance precision medicine development for cancer patients.

BlueGenes and Levrx Partner to Integrate Real-Time Pharmacogenetic Testing into Pharmacy Benefit Systems

Precision Medicine
  • BlueGenes and Levrx Technology have formed a strategic partnership to integrate real-time genetic testing insights into pharmacy benefit systems, aiming to accelerate personalized prescribing adoption.
  • The collaboration addresses the critical issue of adverse drug reactions, which cause more than 100,000 deaths annually in the U.S., with BlueGenes targeting a 50% reduction in these fatalities.
  • The integrated solution identifies genetic risks and safer medication alternatives during claims processing, delivering actionable insights through Levrx's digital platform without requiring additional platforms or behavior changes from providers.
  • This partnership represents a shift from passive data collection to proactive decision-making in medication safety, potentially establishing a new standard for personalized healthcare delivery.

Biologic Therapies Transform Respiratory Care as Clinicians Embrace Earlier, Precision-Based Treatment Strategies

Precision MedicineDrug Approval
  • Biologic therapies including dupilumab, benralizumab, and tezepelumab have revolutionized asthma management by enabling biomarker-driven treatment strategies beyond traditional allergen or eosinophil-based models.
  • Dupilumab's 2024 FDA approval for eosinophilic COPD represents the first biologic therapy for this condition, marking a significant milestone in a field where treatment had previously stagnated.
  • Clinicians are increasingly adopting earlier biologic intervention strategies to minimize steroid exposure and prevent long-term adverse outcomes, with pulmonologists now managing biologics more independently.
  • The recognition of asthma and COPD as heterogeneous diseases with overlapping inflammatory pathways is driving a shift toward personalized medicine approaches guided by biomarkers like eosinophils and FeNO.

MRD Testing Emerges as Key Decision Tool for Post-Transplant Multiple Myeloma Management

Precision Medicine
  • MRD testing is gaining clinical importance for treatment decisions following autologous stem cell transplant in multiple myeloma patients, with FDA approval as an endpoint.
  • High-risk patients who fail to achieve MRD negativity after transplant require treatment intensification, while those with sustained MRD negativity may be candidates for treatment discontinuation.
  • Sustained MRD negativity over 2-4 years offers potential for treatment-free intervals, providing both clinical benefits for patients experiencing adverse effects and economic advantages for healthcare systems.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy